Skip to main content

Summary of the European public assessment report (EPAR) for Erbitux

European Medicines Agency

This is a summary of the European public assessment report (EPAR) for Erbitux. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Erbitux.

View other News Articles